Fig. 1 · Structure

Documents & Downloads

Tolterodine tartrate (Detrol LA)

Cat. No. A10937 CAS 124937-52-6

muscarinic receptor antagonist

Tolterodine tartrate (Detrol LA) is a muscarinic receptor antagonist which is used for the treatment of urinary incontinence.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
AChR

Tolterodine tartrate (Detrol LA) Research Summary

This section summarizes 3 in vitro studies of Tolterodine tartrate (Detrol LA) from 2 published references. In vitro models include human ventricular trabeculae.

Tolterodine tartrate (Detrol LA) In Vitro Studies

In human ventricular trabeculae, sequential and cumulative application of Tolterodine increased AP repolarization duration relative to the vehicle control period, predominantly prolonging phase 3 without notably affecting phase 2. Tolterodine had negligible effects on AP amplitude up to the highest tested concentration, 1 μM, compared with the vehicle control period. In acute parasagittal slices from the rostral pole of the gerbil AVCN, Tolterodine washin slightly decreased membrane resistance relative to control, but the difference was not statistically significant. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Tolterodine and ventricular action potential repolarization

Cell-based study · human ventricular trabeculae [1]

In human ventricular trabeculae, sequential and cumulative application of Tolterodine at 0.1 μM and 1 μM increased action potential repolarization duration compared with the vehicle control period.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
duration of AP repolarizationReported result tolterodine increased the duration of AP repolarization at 0.1 μM and 1 μM with predominant prolongations of phase 3 without notably affecting phase 2.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 and 1 μM
Exposure duration
Each concentration was applied for 31 min
Method
applied sequentially and cumulatively
Vehicle
Tyrode with 0.1% DMSO
Co-treatment
Other interventions in this design: Stimulation 1 Hz. Compound effect isolated by the comparison: vehicle control period.
Methods and source locations

Compound reported in the paper: Tolterodine

The paper names Tolterodine without stating the salt or form; not verified as the tartrate form supplied as A10937. No dose conversion or lot validation.

Methods > Recording of action potentials in human ventricular trabeculae (S33, S34); Methods > Data analysis (S38); Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S51, S53); Figure 2 legend (S91, S92); Figure 5 legend (S101)

duration of AP repolarization: duration of AP repolarization; comparator: vehicle control solution (Tyrode with 0.1% DMSO) — Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S53)

Tolterodine and ventricular action potential amplitude

Cell-based study · human ventricular trabeculae [1]

In human ventricular trabeculae, sequential and cumulative application of Tolterodine up to 1 μM had negligible effects on action potential amplitude compared with the vehicle control period.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
amplitude of APReported result tolterodine had negligible effects on the amplitude of AP up to the highest testing concentration, 1 μM.[1]

Literature-Reported Treatment Conditions

Treatment concentration
up to the highest testing concentration, 1 μM
Exposure duration
Each concentration was applied for 31 min
Method
applied sequentially and cumulatively
Vehicle
Tyrode with 0.1% DMSO
Co-treatment
Other interventions in this design: Stimulation 1 Hz. Compound effect isolated by the comparison: vehicle control period.
Methods and source locations

Compound reported in the paper: Tolterodine

The paper names Tolterodine without stating the salt or form; not verified as the tartrate form supplied as A10937. No dose conversion or lot validation.

Methods > Recording of action potentials in human ventricular trabeculae (S33, S34); Methods > Data analysis (S38); Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S51, S54); Figure 2 legend (S91, S92); Figure 5 legend (S101)

amplitude of AP: amplitude of AP; comparator: vehicle control solution (Tyrode with 0.1% DMSO) — Results > Effect of tolterodine and terodiline on AP in human ventricular trabeculae (S54)

Tolterodine and membrane resistance in gerbil AVCN slices

Cell-based study · acute parasagittal slices were performed at the rostral pole of the gerbil AVCN (P14–P25) [2]

In acute parasagittal slices from the rostral pole of the gerbil AVCN, Tolterodine was administered by washin at 100 nm. Membrane resistance decreased slightly relative to control, but the difference was not statistically significant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
membrane resistanceRm 100 nm tolterodine; 37°C; during (Tol, 4-14min): 62 ± 14 MΩ[2]

Literature-Reported Treatment Conditions

Exposure duration
during (Tol, 4-14min)
Method
washin
Co-treatment
Other interventions in this design: strychnine 1 µm; gabazine 10 µm; CGP-55845 2 µm. Compound effect isolated by the comparison: control, 69 ± 9 MΩ; tolterodine, 62 ± 14 MΩ.
Reported limits
Not stated in the sentences used: vehicle. Concentration removed by unit check.
Methods and source locations

Compound reported in the paper: Tolterodine

The paper names Tolterodine without stating the salt or form; not verified as the tartrate form supplied as A10937. No dose conversion or lot validation.

Materials and Methods > Electrophysiology (S12, S14, S15); Results (S106); Results > Muscarinic acetylcholine receptors mediate a long-lasting RMP modulation (S162, S163, S166, S167); Figure 4. legend (S308, S310, S313, S314)

membrane resistance: membrane resistance; comparator: control, 69 ± 9 MΩ — Materials and Methods > Electrophysiology (S15); Results > Muscarinic acetylcholine receptors mediate a long-lasting RMP modulation (S162, S163, S167); Figure 4. legend (S308, S310, S313, S314)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 124937-52-6
Applications muscarinic receptor antagonist
Formula C26H37NO7
Molecular Weight 475.6
Synonyms Detrol LA
SMILES
CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 94 mg/mL (197.66 mM)
Water 17 mg/mL (35.74 mM)
Ethanol 6 mg/mL (12.61 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tolterodine tartrate (Detrol LA) Research References

  1. [1] Qu Y, Page G, Abi-Gerges N, et al. Action Potential Recording and Pro-arrhythmia Risk Analysis in Human Ventricular Trabeculae. Front Physiol (2017). PMID: 29354071 DOI: 10.3389/fphys.2017.01109 Source material
  2. [2] Goyer D, Kurth S, Gillet C, et al. Slow Cholinergic Modulation of Spike Probability in Ultra-Fast Time-Coding Sensory Neurons. eNeuro (2016). PMID: 27699207 DOI: 10.1523/ENEURO.0186-16.2016 Source material

Added to your cart

View Cart Checkout
Loading...